GWT-Tud GmbH

The site is evaluating the long‑term safety and tolerability of inhaled treprostinil in patients with idiopathic pulmonary fibrosis and progressive pulmonary fibrosis.

• Assess safety over extended use
• Monitor lung function stability
• Collect real‑world patient outcomes

This work supports the development of inhaled therapies for chronic respiratory conditions.

A study is examining the long‑term tolerability, safety and efficacy of oral nerandomilast for individuals with idiopathic pulmonary fibrosis and other progressive fibrosing interstitial lung diseases.

• Evaluate chronic treatment adherence
• Track disease progression markers
• Determine quality‑of‑life impacts

Results may broaden therapeutic options beyond inhaled agents.

Researchers are characterizing how bexotegrast influences forced vital capacity in participants with idiopathic pulmonary fibrosis over a one‑year period.

• Compare against placebo
• Measure changes in lung volume
• Assess safety profile

Findings could inform dosing strategies for antifibrotic drugs.

A trial is testing whether BI 1015550 can reduce the decline in lung function for patients with progressive fibrosing interstitial lung diseases.

• Primary focus on FVC change
• Safety monitoring throughout study
• Long‑term follow‑up for durability

Success would add a novel oral option for a disease with limited treatments.

The study aims to demonstrate the superiority of inhaled treprostinil over placebo in improving forced vital capacity for subjects with progressive pulmonary fibrosis.

• 52‑week assessment of lung function
• Safety and tolerability endpoints
• Patient‑reported outcomes collection

Positive results could support regulatory approval for this indication.

Investigators are estimating the difference in forced vital capacity after 12 weeks of treatment with BI 765423 compared with placebo in idiopathic pulmonary fibrosis patients.

• Short‑term efficacy readout
• Adverse event tracking
• Potential combination with standard care

The outcome may guide further development of this candidate.

The department focuses on respiratory tract diseases, especially fibrotic lung conditions such as idiopathic pulmonary fibrosis and progressive fibrosing interstitial lung diseases.

• Seven active clinical trials
• Collaboration among three investigators
• Integration of inhaled and oral therapeutic approaches

This portfolio reflects a commitment to improving outcomes for patients with chronic lung fibrosis.